Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

iously received radiotherapy.

This clinical trial has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with paclitaxel and carboplatin every three weeks. Standard dosages of paclitaxel and carboplatin were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further 12 patients at the maximum dosage of REOLYSIN(R) in combination with a standard dosage of paclitaxel and carboplatin.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours such as head and neck, melanoma, lung and ovarian cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

Collaborations - Results

On April 15, 2008, we announced that a poster presentation by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled "Radiation in Combination with Reolysin for Pediatric Sarcomas" was presented at the American Association for Cancer Research ("AACR") Annual Meeting. The poster covers preclinical work using reovirus in combination with radiation in mice implanted with pediatric rhabdomyosarcoma and Ewing's sarcoma tumours. The results demonstrated that the combination of reovirus and radiation significantly enhanced efficacy compared to either treatment alone in terms of tumour regression and event-free survival.

On April 15, 2008, we announced tha
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 The North ... segments the market for detailed analysis of the ... market to reach $616.3 million by 2018, growing ... 2018. , Browse through the TOC of the ... get an idea of the in-depth analysis and ...
(Date:11/26/2014)... -- The announced sales of three healthcare units within ... expand in non-healthcare areas, says Kalorama Information. Siemens hasn,t ... says that  Siemens is the third largest company in ... IVD market , with 5.5 billion in IVD revenues ... likely affect IVD market shares.  Siemens ...
(Date:11/26/2014)... 26, 2014 The Alliance for ... survey of European physicians at the "1 ST ... Biological Therapies" at the Spanish Ministry of Health, ... EuropaBio and the Spanish Bioindustry Association (ASEBIO), included ... from Spanish oncology and rheumatology societies, representatives from ...
(Date:11/26/2014)... November 26, 2014 The ETC ... award-winning technology innovation centers, announced today that applications ... on December 1st. “Do you have a big ... I want to know about it. AccelerateBaltimore helps ... to product in just 13 weeks.” Interested ...
Breaking Biology Technology:The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2ASBM Presents European Physicians Survey at Spanish Ministry of Health 2AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3
... , IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC ... fuel paradigm through the production of ethanol from non-food cellulosic wastes, ... list of the "50 Hottest Companies in Bioenergy;" the company,s second ... BlueFire Ethanol among the top 20 bioenergy companies for two straight ...
... PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: ... voluntary recall of five lots and voluntary market withdrawal of ... . Shire is taking this action because some Daytrana patches ... their release liner removal specification, and as a result, patients ...
... , COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation ... the results of its fourth quarter and fiscal year 2009 on ... Following the release, at 4:45 p.m. ET Martek will conduct a ... parties may listen to the call live via webcast by visiting ...
Cached Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... from Johns Hopkins has convinced an international group of ... biomarkers and instead begin a 7,000-hour slog through a ... decode and analyze the molecules that might herald the ... resources available for the exhaustive and expensive testing that ...
... an imprint of Elsevier, announced today that its flagship journal, ... and The American Journal of Human Genetics , were ... in Biology and Medicine of the past century. The ... the SLA,s Biomedical and Life Sciences Division (DBIO) on the ...
... new study by researchers from UC Santa Barbara,s National Center ... threats to the world,s endangered coral reef ecosystems can be ... journal Coral Reefs , lead authors Kimberly A. Selkoe ... maps of the Northwestern Hawaiian Islands (NWHI) a vast ...
Cached Biology News:Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection 2Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection 33 prominent Cell Press journals named among the 100 most influential journals in past 100 years 2The fragility of the world's coral is revealed through a study of the Northwestern Hawaiian Islands 2The fragility of the world's coral is revealed through a study of the Northwestern Hawaiian Islands 3
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA Detection ...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Biology Products: